Aurinia Pharmaceuticals (NASDAQ:AUPH) Cut to “Buy” at StockNews.com

StockNews.com lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a report issued on Monday.

Aurinia Pharmaceuticals Trading Up 2.6 %

Shares of AUPH opened at $7.81 on Monday. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.67. The stock’s fifty day simple moving average is $8.55 and its 200-day simple moving average is $7.60. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.12 billion, a PE ratio of -52.06 and a beta of 1.22.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Large investors have recently modified their holdings of the business. State Street Corp increased its holdings in shares of Aurinia Pharmaceuticals by 2.3% in the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after acquiring an additional 64,949 shares in the last quarter. Barclays PLC grew its holdings in shares of Aurinia Pharmaceuticals by 187.6% during the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock worth $1,607,000 after buying an additional 143,072 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Aurinia Pharmaceuticals during the third quarter worth about $3,330,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Aurinia Pharmaceuticals by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after buying an additional 89,940 shares in the last quarter. Finally, PDT Partners LLC grew its holdings in shares of Aurinia Pharmaceuticals by 76.0% during the third quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock worth $2,210,000 after buying an additional 130,204 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.